Bringing 3D tumor models to the clinic – predictive value for personalized medicine

Biotechnology Journal

Volumn 12, Issue 2, 2017, Pages

  Halfter, Kathrin ^a   Mayer, Barbara ^a,b  

^a Spherotec GmbH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

3D cell culture; Antitumor drug screening; Personalized medicine; Predictive biomarker

Indexed keywords

ASSAYS; BIOMARKERS; CELL CULTURE; CLINICAL RESEARCH; DISEASES; DRUG THERAPY; INFORMATION MANAGEMENT; TUMORS;

3-D CELL CULTURE; ANTITUMOR DRUGS; CLINICAL DIAGNOSTICS; CLINICAL VALIDATIONS; PERSONALIZED MEDICINES; PRE-CLINICAL TESTING; THREE-DIMENSIONAL (3D) CELL CULTURE; TUMOR MICROENVIRONMENT;

DIAGNOSIS;

ANTINEOPLASTIC AGENT; TUMOR MARKER;

ANIMAL MODEL; ASSAY; CANCER THERAPY; CHEMOFX ASSAY; DRUG SELECTIVITY; EVA PCD ASSAY; EXTREME DRUG RESISTANCE ASSAY; HEALTH INSURANCE; HISTOCULTURE DRUG RESISTANCE ASSAY; HUMAN; IN VITRO STUDY; MICROCULTURE KINETIC ASSAY; NONHUMAN; PERSONALIZED MEDICINE; PHYSICIAN; PRECLINICAL STUDY; PREDICTIVE VALUE; PRIMARY CELL CULTURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; THREE DIMENSIONAL TUMOR CELL CULTURE MODEL; TREATMENT OUTCOME; TREND STUDY; TUMOR MICROENVIRONMENT; TUMOR MODEL; VALIDATION STUDY; BIOLOGICAL MODEL; CELL CULTURE TECHNIQUE; PROCEDURES; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CELL CULTURE TECHNIQUES; HUMANS; MODELS, BIOLOGICAL; PRECISION MEDICINE; TUMOR CELLS, CULTURED;

EID: 85010369646     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201600295     Document Type: Review

References (182)

1. Irvin, W., Jr., Muss, H. B., Mayer, D. K., Symptom management in metastatic breast cancer. Oncologist 2011, 16, 1203–1214.
2. Saad, E. D., Katz, A., Buyse, M., Overall survival and post-progression survival in advanced breast cancer: A review of recent randomized clinical trials. J. Clin. Oncol. 2010, 28, 1958–1962.
3. Deng, X., Nakamura, Y., Cancer precision medicine: From cancer screening to drug selection and personalized immunotherapy. Trends Pharmacol. Sci. 2016.
4. Brewer, J. R., Morrison, G., Dolan, M. E., Fleming, G. F., Chemotherapy-induced peripheral neuropathy: Current status and progress. Gynecol. Oncol. 2016, 140, 176–183.
5. Schneider, B. P., Hershman, D. L., Loprinzi, C., Symptoms: Chemotherapy-induced peripheral neuropathy. Adv. Exp. Med. Biol. 2015, 862, 77–87.
6. Perrino, C., Schiattarella, G. G., Magliulo, F., Ilardi, F. et al., Cardiac side effects of chemotherapy: State of art and strategies for a correct management. Curr. Vasc. Pharmacol. 2014, 12, 106–116.
7. Shapiro, C. L., Recht, A., Side effects of adjuvant treatment of breast cancer. N. Engl. J. Med. 2001, 344, 1997–2008.
8. Hubbard, J., Thomas, D. M., Yothers, G., Green, E. et al., Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: Findings from the Adjuvant Colon Cancer Endpoints data set. J. Clin. Oncol. 2012, 30, 2334–2339.
9. Wisnivesky, J. P., Smith, C. B., Packer, S., Strauss, G. M. et al., Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II-IIIA lung cancer: Observational cohort study. BMJ 2011, 343, d4013.
10. Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H. S. et al., Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: Final results from the EGF104900 Study. J. Clin. Oncol. 2012, 30, 2585–2592.
11. Zhang, X., Zhang, X. J., Zhang, T. Y., Yu, F. F. et al., Effect and safety of dual anti-human epidermal growth factor receptor 2 therapy compared to monotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: A systematic review. BMC Cancer 2014, 14, 625.
12. Dancey, J., Sausville, E. A., Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Rev. Drug Discovery 2003, 2, 296–313.
13. Schramm, A., De Gregorio, N., Widschwendter, P., Fink, V., Huober, J., Targeted therapies in HER2-positive breast cancer – a systematic review. Breast Care (Basel) 2015, 10, 173–178.
14. Fisher, B., Jeong, J. H., Anderson, S., Wolmark, N., Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: Updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. J. Natl. Cancer Inst. 2004, 96, 1823–1831.
15. Buzdar, A. U., Ibrahim, N. K., Francis, D., Booser, D. J. et al., Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J. Clin. Oncol. 2005, 23, 3676–3685.
16. Gianni, L., Eiermann, W., Semiglazov, V., Manikhas, A. et al., Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010, 375, 377–384.
17. Pierga, J. Y., Delaloge, S., Espie, M., Brain, E. et al., A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res. Treat. 2010, 122, 429–437.
18. Bang, Y. J., Van Cutsem, E., Feyereislova, A., Chung, H. C. et al., Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010, 376, 687–697.
19. Heydt, C., Kostenko, A., Merkelbach-Bruse, S., Wolf, J., Buttner, R., ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): The Cologne model for implementing personalised oncology. Ann. Oncol. 2016, 27 Suppl. 3, iii25-iii34.
20. Sievers, C. K., Kratz, J. D., Zurbriggen, L. D., LoConte, N. K. et al., The multidisciplinary management of colorectal cancer: Present and future paradigms. Clin. Colon Rectal Surg. 2016, 29, 232–238.
21. Dunnwald, L. K., Rossing, M. A., Li, C. I., Hormone receptor status, tumor characteristics, and prognosis: A prospective cohort of breast cancer patients. Breast Cancer Res. 2007, 9, R6.
22. Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B. et al., Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011, 364, 2507–2516.
23. Wong, D. J., Ribas, A., Targeted therapy for melanoma. Cancer Treat. Res. 2016, 167, 251–262.
24. Tsao, M. S., Sakurada, A., Cutz, J. C., Zhu, C. Q. et al., Erlotinib in lung cancer – molecular and clinical predictors of outcome. N. Engl. J. Med. 2005, 353, 133–144.
25. Ledermann, J. A., PARP inhibitors in ovarian cancer. Ann. Oncol. 2016, 27 Suppl. 1, i40-i44.
26. Wells, S. A., Jr., Robinson, B. G., Gagel, R. F., Dralle, H. et al., Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial. J. Clin. Oncol. 2012, 30, 134–141.
27. Moslehi, J. J., Cardiovascular Toxic Effects of Targeted Cancer Therapies. N. Engl. J. Med. 2016, 375, 1457–1467.
28. Oostendorp, L. J., Stalmeier, P. F., Donders, A. R., van der Graaf, W. T., Ottevanger, P. B., Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: A systematic review. Lancet Oncol. 2011, 12, 1053–1061.
29. e.V., A. e. V. i. d. D. e. V. s. i. d. D., Guidelines Breast 2014.
30. Theriault, R. L., Carlson, R. W., Allred, C., Anderson, B. O. et al., Breast cancer, version 3.2013: Featured updates to the NCCN guidelines. J. Natl. Compr. Cancer Network 2013, 11, 753–760; quiz 761.
31. Gagliato, D. M., Jardim, D. L., Marchesi, M. S., Hortobagyi, G. N., Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer. Oncotarget 2016.
32. Yadav, V. K., Kumar, A., Mann, A., Aggarwal, S. et al., Engineered reversal of drug resistance in cancer cells – metastases suppressor factors as change agents. Nucleic Acids Res. 2014, 42, 764–773.
33. Eccles, B. K., Geldart, T. R., Laurence, V. M., Bradley, K. L., Lwin, M. T., Experience of first- and subsequent-line systemic therapy in the treatment of non-small cell lung cancer. Ther. Adv. Med. Oncol. 2011, 3, 163–170.
34. Molina-Garrido, M. J., Guillen-Ponce, C., Castellano, C. S., Errasquin, B. M. et al., Tools for decision-making in older cancer patients. Role of the comprehensive geriatric assessment. Anticancer Agents Med. Chem. 2014, 14, 651–656.
35. Dumas, L., Ring, A., Butler, J., Kalsi, T. et al., Improving outcomes for older women with gynaecological malignancies. Cancer Treat. Rev. 2016, 50, 99–108.
36. Caillet, P., Laurent, M., Bastuji-Garin, S., Liuu, E. et al., Optimal management of elderly cancer patients: Usefulness of the Comprehensive Geriatric Assessment. Clin. Interv. Aging 2014, 9, 1645–1660.
37. Hartmann, J. T., Lipp, H. P., Toxicity of platinum compounds. Expert Opin. Pharmacother. 2003, 4, 889–901.
38. Biganzoli, L., Aapro, M., Loibl, S., Wildiers, H., Brain, E., Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force. Cancer Treat Rev. 2016, 43, 19–26.
39. Joerger, M., Treatment regimens of classical and newer taxanes. Cancer Chemother. Pharmacol. 2016, 77, 221–233.
40. Piekarski, M., Jelinska, A., Anthracyclines still prove effective in anticancer therapy. Mini Rev. Med. Chem. 2013, 13, 627–634.
41. Cortes-Funes, H., Coronado, C., Role of anthracyclines in the era of targeted therapy. Cardiovasc. Toxicol. 2007, 7, 56–60.
42. Ballman, K. V., Biomarker: Predictive or prognostic. J. Clin. Oncol. 2015, 33, 3968–3971.
43. Harris, L., Fritsche, H., Mennel, R., Norton, L. et al., American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 2007, 25, 5287–5312.
44. Hayes, D. F., Bast, R. C., Desch, C. E., Fritsche, H., Jr. et al., Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J. Natl. Cancer Inst. 1996, 88, 1456–1466.
45. McShane, L. M., Hayes, D. F., Publication of tumor marker research results: The necessity for complete and transparent reporting. J. Clin. Oncol. 2012, 30, 4223–4232.
46. Duffy, M. J., Sturgeon, C. M., Soletormos, G., Barak, V. et al., Validation of new cancer biomarkers: A position statement from the European group on tumor markers. Clin. Chem. 2015, 61, 809–820.
47. Patil, H., Saxena, S. G., Barrow, C. J., Kanwar, J. R. et al., Chasing the personalized medicine dream through biomarker validation in colorectal cancer. Drug Discovery Today 2016.
48. Cancer Genome Atlas, N., Comprehensive molecular portraits of human breast tumours. Nature 2012, 490, 61–70.
49. Galanina, N., Bossuyt, V., Harris, L. N., Molecular predictors of response to therapy for breast cancer. Cancer J. 2011, 17, 96–103.
50. Kelly, C. M., Warner, E., Tsoi, D. T., Verma, S., Pritchard, K. I., Review of the clinical studies using the 21-gene assay. Oncologist 2010, 15, 447–456.
51. Mamounas, E. P., Tang, G., Fisher, B., Paik, S. et al., Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: Results from NSABP B-14 and NSABP B-20. J. Clin. Oncol. 2010, 28, 1677–1683.
52. Wallden, B., Storhoff, J., Nielsen, T., Dowidar, N. et al., Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Med. Genomics 2015, 8, 54.
53. Khoury, M. J., Coates, R. J., Evans, J. P., Evidence-based classification of recommendations on use of genomic tests in clinical practice: Dealing with insufficient evidence. Genet. Med. 2010, 12, 680–683.
54. Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N. et al., Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 2005, 11, 5678–5685.
55. Bartlett, J. M., Bayani, J., Marshall, A., Dunn, J. A. et al., Comparing breast cancer multiparameter tests in the OPTIMA Prelim Trial: No test is more equal than the others. J. Natl. Cancer Inst. 2016, 108, djw050.
56. Michiels, S., Ternes, N., Rotolo, F., Statistical controversies in clinical research: Prognostic gene signatures are not (yet) useful in clinical practice. Ann. Oncol. 2016, 2016, mdw307.
57. Guinney, J., Dienstmann, R., Wang, X., de Reynies, A. et al., The consensus molecular subtypes of colorectal cancer. Nat. Med. 2015, 21, 1350–1356.
58. Waddell, N., Pajic, M., Patch, A. M., Chang, D. K. et al., Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015, 518, 495–501.
59. Shibata, T., Current and future molecular profiling of cancer by next-generation sequencing. Jpn. J. Clin. Oncol. 2015, 45, 895–899.
60. Leveque, D., Off-label use of targeted therapies in oncology. World Journal Of Clinical Oncology 2016, 7, 253–257.
61. Le Tourneau, C., Delord, J. P., Goncalves, A., Gavoille, C. et al., Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): A multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015, 16, 1324–1334.
62. Hamel, S., McNair, D. S., Birkett, N. J., Mattison, D. R. et al., Off-label use of cancer therapies in women diagnosed with breast cancer in the United States. Springerplus 2015, 4, 209.
63. Tannock, I. F., Hickman, J. A., Limits to Personalized Cancer Medicine. N. Engl. J. Med. 2016, 375, 1289–1294.
64. Merlo, L. M., Pepper, J. W., Reid, B. J., Maley, C. C., Cancer as an evolutionary and ecological process. Nat. Rev. Cancer 2006, 6, 924–935.
65. Nik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M. et al., Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 2016, 534, 47–54.
66. Vogelstein, B., Kinzler, K. W., The Path to Cancer – Three Strikes and You're Out. N. Engl. J. Med. 2015, 373, 1895–1898.
67. Samatov, T. R., Galatenko, V. V., Block, A., Shkurnikov, M. Y. et al., Novel biomarkers in cancer: The whole is greater than the sum of its parts. Semin. Cancer Biol. 2016.
68. Morgan, M. M., Johnson, B. P., Livingston, M. K., Schuler, L. A. et al., Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvement. Pharmacol. Ther. 2016, 165, 79–92.
69. Lam, S. W., Jimenez, C. R., Boven, E., Breast cancer classification by proteomic technologies: Current state of knowledge. Cancer Treat. Rev. 2014, 40, 129–138.
70. Du, W., Elemento, O., Cancer systems biology: Embracing complexity to develop better anticancer therapeutic strategies. Oncogene 2015, 34, 3215–3225.
71. Mertins, P., Mani, D. R., Ruggles, K. V., Gillette, M. A. et al., Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 2016, 534, 55–62.
72. Tang, X., Lin, C. C., Spasojevic, I., Iversen, E. S. et al., A joint analysis of metabolomics and genetics of breast cancer. Breast Cancer Res. 2014, 16, 415.
73. Janowczyk, A., Madabhushi, A., Deep learning for digital pathology image analysis: A comprehensive tutorial with selected use cases. J. Pathol. Inform. 2016, 7, 29.
74. Herr, T. M., Bielinski, S. J., Bottinger, E., Brautbar, A. et al., A conceptual model for translating omic data into clinical action. J. Pathol. Inform. 2015, 6, 46.
75. Nath, S., Devi, G. R., Three-dimensional culture systems in cancer research: Focus on tumor spheroid model. Pharmacol. Ther. 2016, 163, 94–108.
76. Dairkee, S. H., Deng, G., Stampfer, M. R., Waldman, F. M., Smith, H. S., Selective cell culture of primary breast carcinoma. Cancer Res. 1995, 55, 2516–2519.
77. Mitra, A., Mishra, L., Li, S., Technologies for deriving primary tumor cells for use in personalized cancer therapy. Trends Biotechnol. 2013, 31, 347–354.
78. Goubran, H. A., Kotb, R. R., Stakiw, J., Emara, M. E., Burnouf, T., Regulation of tumor growth and metastasis: The role of tumor microenvironment. Cancer Growth Metastasis 2014, 7, 9–18.
79. Quail, D. F., Joyce, J. A., Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 2013, 19, 1423–1437.
80. Weigelt, B., Bissell, M. J., The need for complex 3D culture models to unravel novel pathways and identify accurate biomarkers in breast cancer. Adv. Drug. Delivery Rev. 2014, 69–70, 42–51.
81. Allinen, M., Beroukhim, R., Cai, L., Brennan, C. et al., Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004, 6, 17–32.
82. Froehlich, K., Haeger, J. D., Heger, J., Pastuschek, J. et al., Generation of multicellular breast cancer tumor spheroids: Comparison of different protocols. J. Mammary Gland Biol. Neoplasia 2016.
83. Ruppen, J., Wildhaber, F. D., Strub, C., Hall, S. R. et al., Towards personalized medicine: Chemosensitivity assays of patient lung cancer cell spheroids in a perfused microfluidic platform. Lab Chip 2015, 15, 3076–3085.
84. Weiswald, L. B., Bellet, D., Dangles-Marie, V., Spherical cancer models in tumor biology. Neoplasia 2015, 17, 1–15.
85. Halfter, K., Hoffmann, O., Ditsch, N., Ahne, M. et al., Testing chemotherapy efficacy in HER2 negative breast cancer using patient-derived spheroids. J. Transl. Med. 2016, 14, 112.
86. Burdall, S. E., Hanby, A. M., Lansdown, M. R., Speirs, V., Breast cancer cell lines: Friend or foe. Breast Cancer Res. 2003, 5, 89–95.
87. Weeber, F., van de Wetering, M., Hoogstraat, M., Dijkstra, K. K. et al., Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases. Proc. Natl. Acad. Sci. USA 2015, 112, 13308–13311.
88. Knight, E., Przyborski, S., Advances in 3D cell culture technologies enabling tissue-like structures to be created in vitro. J. Anat. 2015, 227, 746–756.
89. Stadler, M., Walter, S., Walzl, A., Kramer, N. et al., Increased complexity in carcinomas: Analyzing and modeling the interaction of human cancer cells with their microenvironment. Semin. Cancer Biol. 2015, 35, 107–124.
90. Naipal, K. A., Verkaik, N. S., Sanchez, H., van Deurzen, C. H. et al., Tumor slice culture system to assess drug response of primary breast cancer. BMC Cancer 2015, 16, 78.
91. Davies, E. J., Dong, M., Gutekunst, M., Narhi, K. et al., Capturing complex tumour biology in vitro: Histological and molecular characterisation of precision cut slices. Sci. Rep. 2015, 5, 17187.
92. Koerfer, J., Kallendrusch, S., Merz, F., Wittekind, C. et al., Organotypic slice cultures of human gastric and esophagogastric junction cancer. Cancer Med. 2016, 5, 1444–1453.
93. Holliday, D. L., Moss, M. A., Pollock, S., Lane, S. et al., The practicalities of using tissue slices as preclinical organotypic breast cancer models. J. Clin. Pathol. 2013, 66, 253–255.
94. Qureshi-Baig, K., Ullmann, P., Rodriguez, F., Frasquilho, S. et al., What do we learn from spheroid culture systems? Insights from tumorspheres derived from primary colon cancer tissue. PLoS One 2016, 11, e0146052.
95. Vamvakidou, A. P., Mondrinos, M. J., Petushi, S. P., Garcia, F. U. et al., Heterogeneous breast tumoroids: An in vitro assay for investigating cellular heterogeneity and drug delivery. J. Biomol. Screening 2007, 12, 13–20.
96. Fong, E. L., Harrington, D. A., Farach-Carson, M. C., Yu, H., Heralding a new paradigm in 3D tumor modeling. Biomaterials 2016, 108, 197–213.
97. Baker, L. A., Tiriac, H., Clevers, H., Tuveson, D. A., Modeling pancreatic cancer with organoids. Trends Cancer 2016, 2, 176–190.
98. Young, M., Reed, K. R., Organoids as a model for colorectal cancer. Curr. Colorectal Cancer Rep. 2016, 12, 281–287.
99. Golovko, D., Kedrin, D., Yilmaz, O. H., Roper, J., Colorectal cancer models for novel drug discovery. Expert Opin. Drug Discovery 2015, 10, 1217–1229.
100. Lombardo, Y., de Giorgio, A., Coombes, C. R., Stebbing, J., Castellano, L., Mammosphere formation assay from human breast cancer tissues and cell lines. J. Vis. Exp. 2015, 10.3791/52671.
101. Kondo, J., Endo, H., Okuyama, H., Ishikawa, O. et al., Retaining cell-cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer. Proc. Natl. Acad. Sci. USA 2011, 108, 6235–6240.
102. Weiswald, L. B., Richon, S., Massonnet, G., Guinebretiere, J. M. et al., A short-term colorectal cancer sphere culture as a relevant tool for human cancer biology investigation. Br. J. Cancer 2013, 108, 1720–1731.
103. Weiswald, L. B., Richon, S., Validire, P., Briffod, M. et al., Newly characterised ex vivo colospheres as a three-dimensional colon cancer cell model of tumour aggressiveness. Br. J. Cancer 2009, 101, 473–482.
104. Lin, R. Z., Chang, H. Y., Recent advances in three-dimensional multicellular spheroid culture for biomedical research. Biotechnol. J. 2008, 3, 1172–1184.
105. Raghavan, S., Mehta, P., Horst, E. N., Ward, M. R. et al., Comparative analysis of tumor spheroid generation techniques for differential in vitro drug toxicity. Oncotarget 2016, 7, 16948–16961.
106. Timmins, N. E., Nielsen, L. K., Generation of multicellular tumor spheroids by the hanging-drop method. Methods Mol. Med. 2007, 140, 141–151.
107. Costa, E. C., Gaspar, V. M., Coutinho, P., Correia, I. J., Optimization of liquid overlay technique to formulate heterogenic 3D co-cultures models. Biotechnol. Bioeng. 2014, 111, 1672–1685.
108. Alessandri, K., Sarangi, B. R., Gurchenkov, V. V., Sinha, B. et al., Cellular capsules as a tool for multicellular spheroid production and for investigating the mechanics of tumor progression in vitro. Proc. Natl. Acad. Sci. USA 2013, 110, 14843–14848.
109. Hirschhaeuser, F., Menne, H., Dittfeld, C., West, J. et al., Multicellular tumor spheroids: An underestimated tool is catching up again. J. Biotechnol. 2010, 148, 3–15.
110. Levinger, I., Ventura, Y., Vago, R., Life is three dimensional-as in vitro cancer cultures should be. Adv. Cancer Res. 2014, 121, 383–414.
111. Herrmann, D., Conway, J. R., Vennin, C., Magenau, A. et al., Three-dimensional cancer models mimic cell-matrix interactions in the tumour microenvironment. Carcinogenesis 2014, 35, 1671–1679.
112. Cree, I. A., Glaysher, S., Harvey, A. L., Efficacy of anti-cancer agents in cell lines versus human primary tumour tissue. Curr. Opin. Pharmacol. 2010, 10, 375–379.
113. Freeman, A. E., Hoffman, R. M., In vivo-like growth of human tumors in vitro. Proc. Natl. Acad. Sci. USA 1986, 83, 2694–2698.
114. Astolfi, M., Peant, B., Lateef, M. A., Rousset, N. et al., Micro-dissected tumor tissues on chip: An ex vivo method for drug testing and personalized therapy. Lab Chip 2016, 16, 312–325.
115. Moraes, C., Labuz, J. M., Leung, B. M., Inoue, M. et al., On being the right size: Scaling effects in designing a human-on-a-chip. Integr. Biol. (Camb.) 2013, 5, 1149–1161.
116. Skardal, A., Devarasetty, M., Forsythe, S., Atala, A., Soker, S., A reductionist metastasis-on-a-chip platform for in vitro tumor progression modeling and drug screening. Biotechnol. Bioeng. 2016.
117. Walsh, A. J., Cook, R. S., Sanders, M. E., Aurisicchio, L. et al., Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer. Cancer Res. 2014, 74, 5184–5194.
118. Hoffmann, O. I., Ilmberger, C., Magosch, S., Joka, M. et al., Impact of the spheroid model complexity on drug response. J. Biotechnol. 2015, 205, 14–23.
119. Vandamme, T. F., Use of rodents as models of human diseases. J. Pharm. Bioallied Sci. 2014, 6, 2–9.
120. DeRose, Y. S., Gligorich, K. M., Wang, G., Georgelas, A. et al., Patient-derived models of human breast cancer: Protocols for in vitro and in vivo applications in tumor biology and translational medicine. Curr. Protoc. Pharmacol. 2013, Chapter 14, Unit14 23.
121. Jonkers, J., Derksen, P. W., Modeling metastatic breast cancer in mice. J. Mammary Gland Biol. Neoplasia 2007, 12, 191–203.
122. Lodhia, K. A., Hadley, A. M., Haluska, P., Scott, C. L., Prioritizing therapeutic targets using patient-derived xenograft models. Biochim. Biophys. Acta 2015, 1855, 223–234.
123. Siolas, D., Hannon, G. J., Patient-derived tumor xenografts: Transforming clinical samples into mouse models. Cancer Res. 2013, 73, 5315–5319.
124. Borowsky, A. D., Choosing a mouse model: Experimental biology in context–the utility and limitations of mouse models of breast cancer. Cold Spring Harbor Perspect. Biol. 2011, 3, a009670.
125. Bock, B. C., Stein, U., Schmitt, C. A., Augustin, H. G., Mouse models of human cancer. Cancer Res. 2014, 74, 4671–4675.
126. Hennighausen, L., Mouse models for breast cancer. Breast Cancer Res. 2000, 2, 2–7.
127. Malaney, P., Nicosia, S. V., Dave, V., One mouse, one patient paradigm: New avatars of personalized cancer therapy. Cancer Lett. 2014, 344, 1–12.
128. Gagliato Dde, M., Gonzalez-Angulo, A. M., Lei, X., Theriault, R. L. et al., Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J. Clin. Oncol. 2014, 32, 735–744.
129. Nachiappan, S., Askari, A., Mamidanna, R., Munasinghe, A. et al., Initiation of adjuvant chemotherapy within 8 weeks of elective colorectal resection improves overall survival regardless of reoperation. Colorectal Dis. 2016, 18, 1041–1049.
130. Singh, S., Guetzko, M., Resnick, K., Preoperative predictors of delay in initiation of adjuvant chemotherapy in patients undergoing primary debulking surgery for ovarian cancer. Gynecol. Oncol. 2016, 143, 241–245.
131. Cassidy, J. W., Caldas, C., Bruna, A., Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts. Cancer Res. 2015, 75, 2963–2968.
132. Cheon, D. J., Orsulic, S., Mouse models of cancer. Annu. Rev. Pathol. 2011, 6, 95–119.
133. Vargo-Gogola, T., Rosen, J. M., Modelling breast cancer: One size does not fit all. Nat. Rev. Cancer 2007, 7, 659–672.
134. Steele, V. E., Lubet, R. A., The use of animal models for cancer chemoprevention drug development. Semin. Oncol. 2010, 37, 327–338.
135. Hidalgo, M., Bruckheimer, E., Rajeshkumar, N. V., Garrido-Laguna, I. et al., A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol. Cancer Ther. 2011, 10, 1311–1316.
136. Unger, F. T., Witte, I., David, K. A., Prediction of individual response to anticancer therapy: Historical and future perspectives. Cell. Mol. Life Sci. 2015, 72, 729–757.
137. Burstein, H. J., Mangu, P. B., Somerfield, M. R., Schrag, D. et al., American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J. Clin. Oncol. 2011, 29, 3328–3330.
138. Bertelsen, C. A., Sondak, V. K., Mann, B. D., Korn, E. L., Kern, D. H., Chemosensitivity testing of human solid tumors. A review of 1582 assays with 258 clinical correlations. Cancer 1984, 53, 1240–1245.
139. Kern, D. H., Bertelsen, C. A., Present status of chemosensitivity assays. Int. Adv. Surg. Oncol. 1984, 7, 187–213.
140. Korn, E. L., Sondak, V. K., Bertelsen, C. A., Kern, D. H., Analysis of the clinical utility of a predictive chemosensitivity assay. Stat. Med. 1985, 4, 527–534.
141. Sondak, V. K., Bertelsen, C. A., Giuliano, A. E., Morton, D. L., Kern, D. H., In vitro sensitivity of breast carcinoma to combination chemotherapy. Curr. Surg. 1984, 41, 470–472.
142. Sondak, V. K., Bertelsen, C. A., Kern, D. H., Morton, D. L., Evolution and clinical application of a rapid chemosensitivity assay. Cancer 1985, 55, 1367–1371.
143. Cortazar, P., Gazdar, A. F., Woods, E., Russell, E. et al., Survival of patients with limited-stage small cell lung cancer treated with individualized chemotherapy selected by in vitro drug sensitivity testing. Clin. Cancer Res. 1997, 3, 741–747.
144. Weisenthal, L. M., Differential staining cytotoxicity assay: A review. Methods Mol. Biol. 2011, 731, 259–283.
145. Nagourney, R. A., Blitzer, J. B., Shuman, R. L., Asciuto, T. J. et al., Functional profiling to select chemotherapy in untreated, advanced or metastatic non-small cell lung cancer. Anticancer Res. 2012, 32, 4453–4460.
146. Csoka, K., Tholander, B., Gerdin, E., de la Torre, M. et al., In vitro determination of cytotoxic drug response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Int. J. Cancer 1997, 72, 1008–1012.
147. Bounaix Morand du Puch, C., Nouaille, M., Giraud, S., Labrunie, A. et al., Chemotherapy outcome predictive effectiveness by the Oncogramme: Pilot trial on stage-IV colorectal cancer. J. Transl. Med. 2016, 14, 10.
148. Richard, S., Wells, A., Connor, J., Price, F., Use of ChemoFx(R) for identification of effective treatments in epithelial ovarian cancer. PLoS Curr. 2015, 7.
149. Rutherford, T., Orr, J., Jr., Grendys, E., Jr., Edwards, R. et al., A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer. Gynecol. Oncol. 2013, 131, 362–367.
150. Mi, Z., Holmes, F. A., Hellerstedt, B., Pippen, J. et al., Feasibility assessment of a chemoresponse assay to predict pathologic response in neoadjuvant chemotherapy for breast cancer patients. Anticancer Res. 2008, 28, 1733–1740.
151. UnitedHealthCare, UnitedHealthCare 2016.
152. Joo, W. D., Lee, J. Y., Kim, J. H., Yoo, H. J. et al., Efficacy of taxane and platinum-based chemotherapy guided by extreme drug resistance assay in patients with epithelial ovarian cancer. J. Gynecol. Oncol. 2009, 20, 96–100.
153. Sondak, V. K., Bertelsen, C. A., Tanigawa, N., Hildebrand-Zanki, S. U. et al., Clinical correlations with chemosensitivities measured in a rapid thymidine incorporation assay. Cancer Res. 1984, 44, 1725–1728.
154. Matsuo, K., Bond, V. K., Im, D. D., Rosenshein, N. B., Prediction of chemotherapy response with platinum and taxane in the advanced stage of ovarian and uterine carcinosarcoma: A clinical implication of in vitro drug resistance assay. Am. J. Clin. Oncol. 2010, 33, 358–363.
155. Mehta, R. S., Bornstein, R., Yu, I. R., Parker, R. J. et al., Breast cancer survival and in vitro tumor response in the extreme drug resistance assay. Breast Cancer Res. Treat. 2001, 66, 225–237.
156. Linz, U., Ulus, B., Neuloh, G., Clusmann, H. et al., Can in-vitro chemoresponse assays help find new treatment regimens for malignant gliomas. Anticancer Drugs 2014, 25, 375–384.
157. Hetland, T. E., Kaern, J., Skrede, M., Sandstad, B. et al., Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index. Cancer Chemother. Pharmacol. 2012, 69, 1307–1314.
158. Cree, I. A., Kurbacher, C. M., Lamont, A., Hindley, A. C. et al., A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer. Anticancer Drugs 2007, 18, 1093–1101.
159. Gwe Ahn, S., Ah Lee, S., Woo Lee, H., Min Lee, H., Jeong, J., In vitro chemoresponse assay based on the intrinsic subtypes in breast cancer. Jpn. J. Clin. Oncol. 2014, 44, 624–631.
160. Singer, C. F., Klinglmuller, F., Stratmann, R., Staudigl, C. et al., Response prediction to neoadjuvant chemotherapy: Comparison between pre-therapeutic gene expression profiles and in vitro chemosensitivity assay. PLoS One 2013, 8, e66573.
161. Zhang, J., Li, H., Heterogeneity of tumor chemosensitivity in ovarian epithelial cancer revealed using the adenosine triphosphate-tumor chemosensitivity assay. Oncol. Lett. 2015, 9, 2374–2380.
162. Halfter, K., Ditsch, N., Kolberg, H. C., Fischer, H. et al., Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy – the SpheroNEO study. BMC Cancer 2015, 15, 519.
163. Furukawa, T., Kubota, T., Hoffman, R. M., Clinical applications of the histoculture drug response assay. Clin. Cancer Res. 1995, 1, 305–311.
164. Jung, P. S., Kim, D. Y., Kim, M. B., Lee, S. W. et al., Progression-free survival is accurately predicted in patients treated with chemotherapy for epithelial ovarian cancer by the histoculture drug response assay in a prospective correlative clinical trial at a single institution. Anticancer Res. 2013, 33, 1029–1034.
165. Yoon, Y. S., Kim, C. W., Roh, S. A., Cho, D. H. et al., Applicability of histoculture drug response assays in colorectal cancer chemotherapy. Anticancer Res. 2012, 32, 3581–3586.
166. Wu, B., Zhu, J. S., Zhang, Y., Shen, W. M., Zhang, Q., Predictive value of MTT assay as an in vitro chemosensitivity testing for gastric cancer: One institution's experience. World J. Gastroenterol. 2008, 14, 3064–3068.
167. Xu, J. M., Song, S. T., Tang, Z. M., Jiang, Z. F. et al., Predictive chemotherapy of advanced breast cancer directed by MTT assay in vitro. Breast Cancer Res. Treat. 1999, 53, 77–85.
168. Bosserman, L., Prendergast, F., Herbst, R., Fleisher, M. et al., The microculture-kinetic (MiCK) assay: The role of a drug-induced apoptosis assay in drug development and clinical care. Cancer Res. 2012, 72, 3901–3905.
169. Salom, E., Penalver, M., Homesley, H., Burrell, M. et al., Correlation of pretreatment drug induced apoptosis in ovarian cancer cells with patient survival and clinical response. J. Transl. Med. 2012, 10, 162.
170. Kawamura, M., Gika, M., Abiko, T., Inoue, Y. et al., Clinical evaluation of chemosensitivity testing for patients with unresectable non-small cell lung cancer (NSCLC) using collagen gel droplet embedded culture drug sensitivity test (CD-DST). Cancer Chemother. Pharmacol. 2007, 59, 507–513.
171. Takebayashi, K., Mekata, E., Sonoda, H., Shimizu, T. et al., Clinical potential of the anticancer drug sensitivity test for patients with synchronous stage IV colorectal cancer. Cancer Chemother. Pharmacol. 2013, 72, 217–222.
172. Higashiyama, M., Oda, K., Okami, J., Maeda, J. et al., In vitro-chemosensitivity test using the collagen gel droplet embedded culture drug test (CD-DST) for malignant pleural mesothelioma: Possibility of clinical application. Ann. Thorac. Cardiovasc. Surg. 2008, 14, 355–362.
173. Oh, B. Y., Lee, W. Y., Jung, S., Hong, H. K. et al., Correlation between tumor engraftment in patient-derived xenograft models and clinical outcomes in colorectal cancer patients. Oncotarget 2015, 6, 16059–16068.
174. Thomas, R. M., Truty, M. J., Kim, M., Kang, Y. et al., The canary in the coal mine: The growth of patient-derived tumorgrafts in mice predicts clinical recurrence after surgical resection of pancreatic ductal adenocarcinoma. Ann. Surg. Oncol. 2015, 22, 1884–1892.
175. Loibl, S., Neoadjuvant treatment of breast cancer: Maximizing pathologic complete response rates to improve prognosis. Curr. Opin. Obstet. Gynecol. 2015, 27, 85–91.
176. Zardavas, D., Piccart, M., Neoadjuvant therapy for breast cancer. Annu. Rev. Med. 2015, 66, 31–48.
177. Pauli, C., Puca, L., Mosquera, J. M., Robinson, B. D. et al., An emerging role for cytopathology in precision oncology. Cancer Cytopathol. 2016, 124, 167–173.
178. Dowlati, A., Haaga, J., Remick, S. C., Spiro, T. P. et al., Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. Clin. Cancer Res. 2001, 7, 2971–2976.
179. Udelnow, A., Schonfelder, M., Wurl, P., Halloul, Z. et al., In vitro chemo-sensitivity assay guided chemotherapy is associated with prolonged overall survival in cancer patients. Pol. Przegl. Chir. 2013, 85, 340–347.
180. Tian, C., Sargent, D. J., Krivak, T. C., Powell, M. A. et al., Evaluation of a chemoresponse assay as a predictive marker in the treatment of recurrent ovarian cancer: Further analysis of a prospective study. Br. J. Cancer 2014, 111, 843–850.
181. von Heideman, A., Tholander, B., Grundmark, B., Cajander, S. et al., Chemotherapeutic drug sensitivity of primary cultures of epithelial ovarian cancer cells from patients in relation to tumour characteristics and therapeutic outcome. Acta Oncol. 2014, 53, 242–250.
182. Rubio-Viqueira, B., Jimeno, A., Cusatis, G., Zhang, X. et al., An in vivo platform for translational drug development in pancreatic cancer. Clin. Cancer Res. 2006, 12, 4652–4661.